| Literature DB >> 27505350 |
Alessia Lasorsa1, Olga Stuchlíková2,3, Viktor Brabec2, Giovanni Natile1, Fabio Arnesano1.
Abstract
Platinum(IV) complexes generally require reduction to reactive Pt(II) species to exert their chemotherapeutic activity. The process of reductive activation of (15)N-labeled (OC-6-43)-bis(acetato)diamminedichloridoplatinum(IV), in the presence of nicotinamide adenine dinucleotide (NADH) and horse heart cytochrome c (cyt c), was monitored by (1)H,(15)N-HSQC NMR spectroscopy and protein digestion experiments. It has been shown that cyt c plays a catalytic role in the transfer of two reducing equivalents from NADH to Pt(IV) species. Noncovalent interactions between reduced monoaqua cisplatin (cis-[PtCl((15)NH3)2(H2O)](+)) and the protein, in the proximity of the heme cofactor, and also covalent binding of platinum to the protein region around Met65 and Met80 take place.Entities:
Keywords: Pt(IV) complexes; anticancer prodrugs; cytochrome c; reductive activation
Mesh:
Substances:
Year: 2016 PMID: 27505350 DOI: 10.1021/acs.molpharmaceut.6b00438
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939